Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.49 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.48 |
| ▸ | USP2 | O75604 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70939 | 0.76 | NPSR1 (0.54) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL70986 | 0.75 | OPRM1 (0.49) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL75647 | 0.75 | OPRL1 (0.71) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL75677 | 0.75 | OPRM1 (0.53) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL61570 | 0.73 | OPRM1 (0.51) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL62422 | 0.73 | OPRL1 (0.69) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL10047375 | 0.71 | NPSR1 (0.61) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL14742155 | 0.70 | CYP3A4 (0.69) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL17542448 | 0.70 | OPRM1 (0.50) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 | |
| SCHEMBL31741187 | 0.69 | NPSR1 (0.47) | OPRM1OPRK1OPRL1CYP2D6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673891-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2394999-B1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO LTD (JP) | 2014-01-29 | — | — | EP | disclosed |
| US-8586591-B2 | Aminopyrazine derivative and medicine | NIPPON SHINYAKU CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | NIPPON SHINYAKU CO., LTD (JP) | 2013-05-23 | — | — | US | disclosed |
| EP-2394999-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131082-A1 | Aminopyrazine Derivative and Medicine | MC2R, AGTR2, AGTR1 | OPRM1 102/4885OPRK1 249/4885OPRL1 194/4885 |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | MC2R, CNR1, NPY2R | OPRM1 76/4885OPRK1 182/4885OPRL1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.